Abstract
This blinded crossover study evaluated the efficacy and pain sensitivity evoked by a previously reported liposome-encapsulated mepivacaine formulation ( 1. Araujo, D. R., Cereda, C. M. S., Brunetto, G. B., Pinto, L. M. A., Santana, M. H. A., de Paula, E. (2004). Encapsulation of mepivacaine prolongs the analgesia provided by sciatic nerve blockade in mice. Can J Anaesth 51:566–572. View all references ). Thirty healthy volunteers received an intraoral injection (1.8 mL), at four different sessions, of the following formulations: 2% mepivacaine with 1:100,000 epinephrine (MVC2%EPI), 3% mepivacaine (MVC3%), and 2 and 3% liposome-encapsulated mepivacaine (MVC2%LUV and MVC3%LUV). Latency period and duration of anesthesia were assessed by an electrical pulp tester and injection discomfort by a visual analog scale (VAS). Data were analyzed with Tukey-Kramer and Friedman tests (P < 0.05). No significant difference was found regarding latency period (in minutes) among the formulations (P > 0.05). The duration of anesthesia after the injection of MVC3%LUV was higher than the one obtained after the infiltration of MVC2%LUV and of MVC3% (P < 0.05). However, the duration of anesthesia obtained with MVC3% did not differ from the one obtained with MVC2%LUV (P > 0.05). MVC3%LUV showed lower VAS median values than MVC2%EPI (P < 0.05), and there were no significant differences among the others formulations. Liposome-encapsulated 3% mepivacaine showed longer duration of anesthesia, in comparison to the commercial formulation of MVC3%. MVC2%LUV was able to produce a similar duration of anesthesia as the 3% commercial formulation, despite the 50% decrease in the anesthetic concentration. Thus, the encapsulation of mepivacaine increased the duration of anesthesia and reduced the injection discomfort caused by vasoconstrictor-associated formulations in healthy volunteers.

This publication has 31 references indexed in Scilit: